



Press Release

Oxford Gene Technology appoints Commercial Director

Oxford, June 6, 2005. Oxford Gene Technology (OGT) is pleased to announce the appointment of James Clough as Commercial Director to drive the commercialisation of technologies and services developed by OGT.

James holds an honours degree from the University of Nottingham and has an accomplished commercial record having held a number of senior roles for companies within the life sciences sector. At GE Healthcare (formerly Amersham Biosciences) he was President of Amersham Biosciences Europe and Vice President of E Business. At Affymetrix he was Vice President and General Manager of European Operations.

"I am excited to be joining OGT to provide commercial focus to the wide range of molecular technologies being developed at OGT for all areas of research. I am looking forward to helping build OGT and developing a significant presence in the life science market", said James.

Mike Evans, OGT's Chief Executive, said "I am delighted to welcome James to OGT. With his track record in commercialising new technology, James will make a major contribution to OGT as it develops products and services for the life science and molecular medicine markets."

About OGT

Oxford Gene Technology (OGT) is a privately owned company founded in 1995 by Professor Sir Edwin Southern. The mission of the company is to develop advanced molecular tools for biologists and to make them widely available through licensing and service activities. The key business areas of OGT include

- licensing which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
- a services business which provides a flexible and cost-effective, customised DNA microarray service covering a range of applications and offers specialist support to assist customers with every aspect of their research.
- Tridend, which is developing 'mass tags' to enhance the amount of information that researchers can generate from mass spectrometry experiments in proteomics and genomics
- Oxamer, which is generating novel array formats based on electrochemical deposition methods for use in life science and diagnostics

OGT's intellectual property covers four general areas that are relevant to the biological sciences; these incorporate microarrays, genomics, proteomics and electrochemistry.

Oxford Gene Technology IP Limited

Begbroke Business and Science Park,

Sandy Lane, Yarnton, Oxford, OX5 1PF UK

Tel: +44 (0) 1865 856 340 Fax: +44 (0) 1865 379 433

Email: info@ogt.co.uk Web: www.ogt.co.uk

- copy ends -

© 2005 kdm communications limited

Editorial contact for further information or follow-up

Lorraine Sharrock at **kdm communications limited**, Milton Keynes, UK

Tel. +44 01908 371173 Fax: +44 01908 37117 email: ideas@kdm-communications.com